Advanced search
Publication Cover
Future Microbiology Volume 6, 2011 - Issue 1
Submit an article Journal homepage
392
Views
0
CrossRef citations to date
0
Altmetric
Review

Future Challenges And Treatment Of Staphylococcus Aureus Bacteremia With Emphasis On MRSA

Rasmus V Rasmussen1 Department of Cardiology,Copenhagen University Hospital,Gentofte, Copenhagen, DenmarkView further author information
,
Vance G Fowler Jr2 Division of Infectious Diseases,Duke University Medical Center,Durham, NC, USAView further author information
,
Robert Skov3 Staphylococcal Laboratory,Statens Serum Institut,Copenhagen, DenmarkView further author information
&
Niels E Bruun1 Department of Cardiology,Copenhagen University Hospital,Gentofte, Copenhagen, DenmarkCorrespondence[email protected]
View further author information
Pages 43-56 | Published online: 16 Dec 2010

Bibliography

  • Biedenbach DJ , MoetGJ, JonesRN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002).Diagn. Microbiol. Infect. Dis.50(1) , 59–69 (2004).
  • Martin GS , ManninoDM, EatonS, MossM: The epidemiology of sepsis in the United States from 1979 through 2000.N. Engl. J. Med.348(16) , 1546–1554 (2003).
  • Lyytikainen O , RuotsalainenE, JarvinenA, ValtonenV, RuutuP: Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995–2001.Eur. J. Clin. Microbiol. Infect. Dis.24(6) , 399–404 (2005).
  • Benfield T , EspersenF, Frimodt-MollerNet al.: Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000.Clin. Microbiol. Infect.13(3) , 257–263 (2007).
  • Fowler VG Jr , OlsenMK, CoreyGRet al.: Clinical identifiers of complicated Staphylococcus aureus bacteremia.Arch. Intern. Med.163(17) , 2066–2072 (2003).
  • Rieg S , Peyerl-HoffmannG, deWith Ket al.: Mortality of S. aureus bacteremia and infectious diseases specialist consultation – a study of 521 patients in Germany.J. Infect.59(4) , 232–239 (2009).
  • Cosgrove SE , SakoulasG, PerencevichENet al.: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.Clin. Infect. Dis.36(1) , 53–59 (2003).
  • Howden BP , DaviesJK, JohnsonPD, StinearTP, GraysonML: Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.Clin. Microbiol. Rev.23(1) , 99–139 (2010).
  • von EC , BeckerK, MachkaK, StammerH, PetersG: Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group.N. Engl. J. Med.344(1) , 11–16 (2001).
  • Wertheim HF , VosMC, OttAet al.: Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers.Lancet364(9435) , 703–705 (2004).
  • Laupland KB , RossT, GregsonDB: Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006.J. Infect. Dis.198(3) , 336–343 (2008).
  • Frimodt-Moller N , EspersenF, SkinhojP, RosdahlVT: Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990.Clin. Microbiol. Infect.3(3) , 297–305 (1997).
  • Banerjee SN , EmoriTG, CulverDHet al.: Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National Nosocomial Infections Surveillance System.Am. J. Med.91(3B) , 86S–89S (1991).
  • Chang FY , MacDonaldBB, PeacockJEJret al. : A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance.Medicine (Baltimore)82(5) , 322–332 (2003).
  • Hill EE , VanderschuerenS, VerhaegenJet al.: Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia.Mayo Clin. Proc.82(10) , 1165–1169 (2007).
  • Jensen AG , WachmannCH, PoulsenKBet al.: Risk factors for hospital-acquired Staphylococcus aureus bacteremia.Arch. Intern. Med.159(13) , 1437–1444 (1999).
  • Benito N , MiroJM, deLazzari Eet al.: Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.Ann. Intern. Med.150(9) , 586–594 (2009).
  • Styers D , SheehanDJ, HoganP, SahmDF: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.Ann. Clin. Microbiol. Antimicrob.5 , 2 (2006).
  • Klevens RM , MorrisonMA, NadleJet al.: Invasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA298(15) , 1763–1771 (2007).
  • Lesens O , HansmannY, BranniganEet al.: Healthcare-associated Staphylococcus aureus bacteremia and the risk for methicillin resistance: is the Centers for Disease Control and Prevention definition for community-acquired bacteremia still appropriate?Infect. Control Hosp. Epidemiol.26(2) , 204–209 (2005).
  • EARSS Management Team: European Antimicrobial Resistance Surveillance System Annual Report 2008. Bilthoven, The Netherlands (2008).
  • Kaiser AM , HaenenAJ, deNeeling AJ, Vandenbroucke-GraulsCM.: Prevalence of methicillin-resistant Staphylococcus aureus and risk factors for carriage in Dutch hospitals.Infect. Control Hosp. Epidemiol.31(11) , 1188–1190 (2010).
  • Moodley A , NightingaleEC, SteggerMet al.: High risk for nasal carriage of methicillin-resistant Staphylococcus aureus among Danish veterinary practitioners.Scand. J. Work Environ. Health34(2) , 151–157 (2008).
  • van Cleef BA , VerkadeEJ, WulfMWet al.: Prevalence of livestock-associated MRSA in communities with high pig-densities in The Netherlands.PLoS ONE5(2) , e9385 (2010).
  • Nickerson EK , WuthiekanunV, DayNP, ChaowagulW, PeacockSJ.: Methicillin-resistant Staphylococcus aureus in rural Asia. Lancet Infect. Dis.6(2) , 70–71 (2006).
  • Nickerson EK , HongsuwanM, LimmathurotsakulDet al.: Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance.PLoS ONE4(1) , e4308 (2009).
  • Nickerson EK , WuthiekanunV, WongsuvanGet al.: Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country.PLoS ONE4(8) , e6512 (2009).
  • Peacock SJ , NewtonPN.: Public health impact of establishing the cause of bacterial infections in rural Asia.Trans. R Soc. Trop. Med. Hyg.102(1) , 5–6 (2008).
  • Daum RS .: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.N. Engl. J. Med.357(4) , 380–390 (2007).
  • Moran GJ , KrishnadasanA, GorwitzRJet al.: Methicillin-resistant S. aureus infections among patients in the emergency department.N. Engl. J. Med.355(7) , 666–674 (2006).
  • Groom AV , WolseyDH, NaimiTSet al.: Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community.JAMA286(10) , 1201–1205 (2001).
  • Kazakova SV , HagemanJC, MatavaMet al.: A clone of methicillin-resistant Staphylococcus aureus among professional football players.N. Engl. J. Med.352(5) , 468–475 (2005).
  • Pan ES , DiepBA, CarletonHAet al.: Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails.Clin. Infect. Dis.37(10) , 1384–1388 (2003).
  • Weber JT : Community-associated methicillin-resistant Staphylococcus aureus.Clin. Infect. Dis.41(Suppl. 4) , S269–S272 (2005).
  • Zinderman CE , ConnerB, MalakootiMAet al.: Community-acquired methicillin-resistant Staphylococcus aureus among military recruits.Emerg. Infect. Dis.10(5) , 941–944 (2004).
  • Diep BA , ChambersHF, GraberCJet al.: Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men.Ann. Intern. Med.148(4) , 249–257 (2008).
  • Gorwitz RJ , Kruszon-MoranD, McAllisterSKet al.: Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004.J. Infect. Dis.197(9) , 1226–1234 (2008).
  • Naimi TS , LeDellKH, Como-SabettiKet al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection.JAMA290(22) , 2976–2984 (2003).
  • McDougal LK , StewardCD, KillgoreGEet al.: Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database.J. Clin. Microbiol.41(11) , 5113–5120 (2003).
  • Tenover FC , McDougalLK, GoeringRVet al.: Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States.J. Clin. Microbiol.44(1) , 108–118 (2006).
  • Liao CH , ChenSY, HuangYT, HsuehPR: Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan.Int. J. Antimicrob. Agents32(4) , 326–332 (2008).
  • Schramm GE , JohnsonJA, DohertyJA, MicekST, KollefMH: Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment.Crit. Care Med.34(8) , 2069–2074 (2006).
  • Miro JM , AngueraI, CabellCHet al.: Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database.Clin. Infect. Dis.41(4) , 507–514 (2005).
  • Rasmussen RV , Snygg-MartinU, OlaisonLet al.: Major cerebral events in Staphylococcus aureus infective endocarditis: is anticoagulant therapy safe?Cardiology114(4) , 284–291 (2009).
  • Roder BL , WandallDA, EspersenFet al.: Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts.Am. J. Med.102(4) , 379–386 (1997).
  • Fowler VG Jr , MiroJM, HoenBet al.: Staphylococcus aureus endocarditis: a consequence of medical progress.JAMA293(24) , 3012–3021 (2005).
  • Darouiche RO : Device-associated infections: a macroproblem that starts with microadherence.Clin. Infect. Dis.33(9) , 1567–1572 (2001).
  • Voigt A , ShalabyA, SabaS: Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003.J. Am. Coll. Cardiol.48(3) , 590–591 (2006).
  • Chamis AL , PetersonGE, CabellCHet al.: Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators.Circulation104(9) , 1029–1033 (2001).
  • El-Ahdab F , BenjaminDKJr , WangAet al.: Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia.Am. J. Med.118(3) , 225–229 (2005).
  • Sohail MR , UslanDZ, KhanAHet al.: Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections.J. Am. Coll. Cardiol.49(18) , 1851–1859 (2007).
  • Uslan DZ , SohailMR, StSauver JLet al.: Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study.Arch. Intern. Med.167(7) , 669–675 (2007).
  • Baddour LM , EpsteinAE, EricksonCCet al.: Update on cardiovascular implantable electronic device infections and their management. a scientific statement from the American Heart Association.Circulation121 , 458–477 (2010).
  • Chu VH , CrosslinDR, FriedmanJYet al.: Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes.Am. J. Med.118(12) , 1416 (2005).
  • Habib G , HoenB, TornosPet al.: Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC).Eur. Heart J.30(19) , 2369–2413 (2009).
  • Wilson W , TaubertKA, GewitzMet al.: Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.Circulation116(15) , 1736–1754 (2007).
  • Abraham J , MansourC, VeledarE, KhanB, LerakisS: Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia.Am. Heart J.147(3) , 536–539 (2004).
  • Fowler VG Jr , LiJ, CoreyGRet al.: Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.J. Am. Coll. Cardiol.30(4) , 1072–1078 (1997).
  • Roder BL , WandallDA, Frimodt-MollerNet al.: Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark.Arch. Intern. Med.159(5) , 462–469 (1999).
  • Casella F , RanaB, CasazzaGet al.: The potential impact of contemporary transthoracic echocardiography on the management of patients with native valve endocarditis: a comparison with transesophageal echocardiography.Echocardiography26(8) , 900–906 (2009).
  • Corey GR : Staphylococcus aureus bloodstream infections: definitions and treatment.Clin. Infect. Dis.48(Suppl. 4) , S254–S259 (2009).
  • Mermel LA , AllonM, BouzaEet al.: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America.Clin. Infect. Dis.49(1) , 1–45 (2009).
  • van BA , MellesDC, NouwenJet al.: Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus.Infect. Genet. Evol.9(1) , 32–47 (2009).
  • Melles DC , GorkinkRF, BoelensHAet al.: Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus.J. Clin. Invest.114(12) , 1732–1740 (2004).
  • Feil EJ , CooperJE, GrundmannHet al.: How clonal is Staphylococcus aureus?J. Bacteriol.185(11) , 3307–3316 (2003).
  • Robinson DA , EnrightMC: Multilocus sequence typing and the evolution of methicillin-resistant Staphylococcus aureus.Clin. Microbiol. Infect.10(2) , 92–97 (2004).
  • Melles DC , TenoverFC, KuehnertMJet al.: Overlapping population structures of nasal isolates of Staphylococcus aureus from healthy Dutch and American individuals.J. Clin. Microbiol.46(1) , 235–241 (2008).
  • Fowler VG Jr , NelsonCL, McIntyreLMet al.: Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection.J. Infect. Dis.196(5) , 738–747 (2007).
  • Peacock SJ , MooreCE, JusticeAet al.: Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus.Infect. Immun.70(9) , 4987–4996 (2002).
  • Campbell SJ , DeshmukhHS, NelsonCLet al.: Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections.J. Clin. Microbiol.46(2) , 678–684 (2008).
  • Harris SR , FeilEJ, HoldenMTet al.: Evolution of MRSA during hospital transmission and intercontinental spread.Science327(5964) , 469–474 (2010).
  • Patti JM , AllenBL, McGavinMJ, HookM: MSCRAMM-mediated adherence of microorganisms to host tissues.Annu. Rev. Microbiol.48 , 585–617 (1994).
  • Miajlovic H , LoughmanA, BrennanM, CoxD, FosterTJ: Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphylococcus aureus clumping factor B.Infect. Immun.75(7) , 3335–3343 (2007).
  • O‘Brien L , KerriganSW, KawGet al.: Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine–aspartate repeat protein SdrE and protein A.Mol. Microbiol.44(4) , 1033–1044 (2002).
  • Sinha B , FrancoisP, QueYAet al.: Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells.Infect. Immun.68(12) , 6871–6878 (2000).
  • Edwards AM , PottsJR, JosefssonE, MasseyRC: Staphylococcus aureus host cell invasion and virulence in sepsis is facilitated by the multiple repeats within FnBPA.PLoS Pathog.6(6) , e1000964 (2010).
  • Foster TJ : The Staphylococcus aureus ‘superbug‘.J. Clin. Invest.114(12) , 1693–1696 (2004).
  • Sabat A , MellesDC, MartirosianGet al.: Distribution of the serine-aspartate repeat protein-encoding sdr genes among nasal-carriage and invasive Staphylococcus aureus strains.J. Clin. Microbiol.44(3) , 1135–1138 (2006).
  • Trad S , AllignetJ, FrangeulLet al.: DNA macroarray for identification and typing of Staphylococcus aureus isolates.J. Clin. Microbiol.42(5) , 2054–2064 (2004).
  • Xiong YQ , FowlerVG, YeamanMRet al.: Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model.J. Infect. Dis.199(2) , 201–208 (2009).
  • Lalani T , FederspielJJ, BoucherHWet al.: Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.J. Clin. Microbiol.46(9) , 2890–2896 (2008).
  • Croze M , DauwalderO, DumitrescuOet al.: Serum antibodies against Panton–Valentine leukocidin in a normal population and during Staphylococcus aureus infection.Clin. Microbiol. Infect.15(2) , 144–148 (2009).
  • Gillet Y , IssartelB, VanhemsPet al.: Association between Staphylococcus aureus strains carrying gene for Panton–Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.Lancet359(9308) , 753–759 (2002).
  • Jahamy H , GangaR, AlRBet al.: Staphylococcus aureus skin/soft-tissue infections: the impact of SCCmec type and Panton–Valentine leukocidin.Scand. J. Infect. Dis.40(8) , 601–606 (2008).
  • Labandeira-Rey M , CouzonF, BoissetSet al.: Staphylococcus aureus Panton–Valentine leukocidin causes necrotizing pneumonia.Science315(5815) , 1130–1133 (2007).
  • Bohach GA , FastDJ, NelsonRD, SchlievertPM: Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.Crit. Rev. Microbiol.17(4) , 251–272 (1990).
  • Murray RJ : Recognition and management of Staphylococcus aureus toxin-mediated disease.Intern. Med. J.35(Suppl. 2) , S106–S119 (2005).
  • Gould IM : Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.Int. J. Antimicrob. Agents31(Suppl. 2) , 1–9 (2008).
  • Chang FY , PeacockJEJr , MusherDMet al.: Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.Medicine (Baltimore)82(5) , 333–339 (2003).
  • Gentry CA , RodvoldKA, NovakRM, HershowRC, NadererOJ: Retrospective evaluation of therapies for Staphylococcus aureus endocarditis.Pharmacotherapy17(5) , 990–997 (1997).
  • Stryjewski ME , SzczechLA, BenjaminDKJret al. : Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.Clin. Infect. Dis.44(2) , 190–196 (2007).
  • Lodise TP , GravesJ, EvansAet al.: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.Antimicrob. Agents Chemother.52(9) , 3315–3320 (2008).
  • Pea F , VialeP: Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of Staphylococcus aureus bacteremia treated with vancomycin?Clin. Infect. Dis.49(4) , 642–643 (2009).
  • Price J , AtkinsonS, LlewelynM, PaulJ: Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.Clin. Infect. Dis.48(7) , 997–998 (2009).
  • Lalueza A , ChavesF, SanJRet al.: Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?J. Infect. Dis.201(2) , 311–312 (2010).
  • Wikler MA , CockerillFR3rd , CraigWAet al.: Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth International Supplement M100-S16.Clinical and Laboratory Standards Institute, PA, USA26(3) , (2006).
  • Appelbaum PC : Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).Int. J. Antimicrob. Agents30(5) , 398–408 (2007).
  • de LA , HidriN, TimsitJFet al.: Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit.Clin. Infect. Dis.42(2) , 170–178 (2006).
  • Garnier F , ChainierD, WalshTet al.: A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.J. Antimicrob. Chemother.57(1) , 146–149 (2006).
  • Maor Y , RahavG, BelausovNet al.: Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.J. Clin. Microbiol.45(5) , 1511–1514 (2007).
  • Bae IG , FederspielJJ, MiroJMet al.: Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.J. Infect. Dis.200(9) , 1355–1366 (2009).
  • Charles PG , WardPB, JohnsonPD, HowdenBP, GraysonML: Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.Clin. Infect. Dis.38(3) , 448–451 (2004).
  • Maor Y , HaginM, BelausovNet al.: Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.J. Infect. Dis.199(5) , 619–624 (2009).
  • Steinkraus G , WhiteR, FriedrichL: Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05.J. Antimicrob. Chemother.60(4) , 788–794 (2007).
  • Wang G , HindlerJF, WardKW, BrucknerDA: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.J. Clin. Microbiol.44(11) , 3883–3886 (2006).
  • Sader HS , FeyPD, FishDNet al.: Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.Antimicrob. Agents Chemother.53(10) , 4127–4132 (2009).
  • Sakoulas G , Moise-BroderPA, SchentagJet al.: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.J. Clin. Microbiol.42(6) , 2398–2402 (2004).
  • Soriano A , MarcoF, MartinezJAet al.: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.Clin. Infect. Dis.46(2) , 193–200 (2008).
  • Rolston KV , NguyenH, AmosGet al.: A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of Gram-positive bacteremia in patients with cancer.J. Infect. Dis.169(2) , 350–355 (1994).
  • Van der AP , AounM, MeunierF: Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts.Antimicrob. Agents Chemother.35(3) , 451–457 (1991).
  • Yalaz M , CetinH, AkisuMet al.: Experience with teicoplanin in the treatment of neonatal staphylococcal sepsis.J. Int. Med. Res.32(5) , 540–548 (2004).
  • Babinchak T , Ellis-GrosseE, DartoisN, RoseGM, LohE: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.Clin. Infect. Dis.41(Suppl. 5) , S354–S367 (2005).
  • Florescu I , BeuranM, DimovRet al.: Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.J. Antimicrob. Chemother.62(Suppl. 1) , i17–i28 (2008).
  • Sacchidanand S , PennRL, EmbilJMet al.: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase 3, randomized, double-blind trial.Int. J. Infect. Dis.9(5) , 251–261 (2005).
  • Stein GE , CraigWA: Tigecycline: a critical analysis.Clin. Infect. Dis.43(4) , 518–524 (2006).
  • Gardiner D , DukartG, CooperA, BabinchakT: Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 Phase III clinical trials.Clin. Infect. Dis.50(2) , 229–238 (2010).
  • Koomanachai P , CrandonJL, NicolauDP: Newer developments in the treatment of Gram-positive infections.Expert Opin. Pharmacother.10(17) , 2829–2843 (2009).
  • Jaksic B , MartinelliG, Perez-OteyzaJet al.: Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.Clin. Infect. Dis.42(5) , 597–607 (2006).
  • Lin DF , ZhangYY, WuJFet al.: Linezolid for the treatment of infections caused by Gram-positive pathogens in China.Int. J. Antimicrob. Agents32(3) , 241–249 (2008).
  • Stevens DL , HerrD, LampirisHet al.: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.Clin. Infect. Dis.34(11) , 1481–1490 (2002).
  • Tascini C , GemignaniG, DoriaRet al.: Linezolid treatment for Gram-positive infections: a retrospective comparison with teicoplanin.J. Chemother.21(3) , 311–316 (2009).
  • Wilcox M , NathwaniD, DrydenM: Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.J. Antimicrob. Chemother.53(2) , 335–344 (2004).
  • Falagas ME , SiemposII, VardakasKZ: Linezolid versus glycopeptide or b-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials.Lancet Infect. Dis.8(1) , 53–66 (2008).
  • Wilcox MH , TackKJ, BouzaEet al.: Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a Phase 3 study.Clin. Infect. Dis.48(2) , 203–212 (2009).
  • Jang HC , KimSH, KimKHet al.: Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.Clin. Infect. Dis.49(3) , 395–401 (2009).
  • Gandelman K , ZhuT, FahmiOAet al.: Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.J. Clin. Pharmacol. DOI: 10.1177/0091270010366445 (2010) (Epub ahead of print).
  • Falagas ME , VardakasKZ: Benefit–risk assessment of linezolid for serious Gram-positive bacterial infections.Drug Saf.31(9) , 753–768 (2008).
  • Sanchez GM , de laTorre MA, MoralesGet al.: Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.JAMA303(22) , 2260–2264 (2010).
  • Morales G , PicazoJJ, BaosEet al.: Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.Clin. Infect. Dis.50(6) , 821–825 (2010).
  • Potoski BA , AdamsJ, ClarkeLet al.: Epidemiological profile of linezolid-resistant coagulase-negative staphylococci.Clin. Infect. Dis.43(2) , 165–171 (2006).
  • Tsiodras S , GoldHS, SakoulasGet al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus.Lancet358(9277) , 207–208 (2001).
  • Silverman JA , PerlmutterNG, ShapiroHM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.Antimicrob. Agents Chemother.47(8) , 2538–2544 (2003).
  • Fowler VG Jr , BoucherHW, CoreyGRet al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.N. Engl. J. Med.355(7) , 653–665 (2006).
  • Papadopoulos S , BallAM, LiewerSEet al.: Rhabdomyolysis during therapy with daptomycin.Clin. Infect. Dis.42(12) , e108–e110 (2006).
  • Patel SJ , SamoTC, SukiWN: Early-onset rhabdomyolysis related to daptomycin use.Int. J. Antimicrob. Agents30(5) , 472–474 (2007).
  • Enoch DA , BygottJM, DalyML, KarasJA: Daptomycin.J. Infect.55(3) , 205–213 (2007).
  • Silverman JA , MortinLI, VanpraaghAD, LiT, AlderJ: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.J. Infect. Dis.191(12) , 2149–2152 (2005).
  • Patel JB , JevittLA, HagemanJ, McDonaldLC, TenoverFC: An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.Clin. Infect. Dis.42(11) , 1652–1653 (2006).
  • Cui L , TominagaE, NeohHM, HiramatsuK: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.Antimicrob. Agents Chemother.50(3) , 1079–1082 (2006).
  • Mwangi MM , WuSW, ZhouYet al.: Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.Proc. Natl Acad. Sci. USA104(22) , 9451–9456 (2007).
  • Stryjewski ME , GrahamDR, WilsonSEet al.: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms.Clin. Infect. Dis.46(11) , 1683–1693 (2008).
  • Stryjewski ME , ChuVH, O‘RiordanWDet al.: Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study.Antimicrob. Agents Chemother.50(3) , 862–867 (2006).
  • Raad I , DarouicheR, VazquezJet al.: Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens.Clin. Infect. Dis.40(3) , 374–380 (2005).
  • Dowell JA , GoldsteinBP, BuckwalterM, StogniewM, DamleB: Pharmacokinetic–pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.J. Clin. Pharmacol.48(9) , 1063–1068 (2008).
  • Barton E , MacGowanA: Future treatment options for Gram-positive infections – looking ahead.Clin. Microbiol. Infect.15(Suppl. 6) , 17–25 (2009).
  • Stryjewski ME , CoreyGR: New treatments for methicillin-resistant Staphylococcus aureus.Curr. Opin. Crit. Care15(5) , 403–412 (2009).
  • Noel GJ , BushK, BagchiP, IanusJ, StraussRS: A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.Clin. Infect. Dis.46(5) , 647–655 (2008).
  • Talbot GH , ThyeD, DasA, GeY: Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.Antimicrob. Agents Chemother.51(10) , 3612–3616 (2007).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.